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Abstract
Quantifying rates governing the clearance of Human Papillomavirus (HPV) and its progression to clinical disease, together
with viral transmissibility and the duration of naturally-acquired immunity, is essential in estimating the impact of
vaccination programmes and screening or testing regimes. However, the complex natural history of HPV makes this difficult.
We infer the viral transmissibility, rate of waning natural immunity and rates of progression and clearance of infection of 13
high-risk and 2 non-oncogenic HPV types, making use of a number of rich datasets from Sweden. Estimates of viral
transmissibility, clearance of initial infection and waning immunity were derived in a Bayesian framework by fitting a
susceptible-infectious-recovered-susceptible (SIRS) transmission model to age- and type-specific HPV prevalence data from
both a cross-sectional study and a randomised controlled trial (RCT) of primary HPV screening. The models fitted well, but
over-estimated the prevalence of four high-risk types with respect to the data. Three of these types (HPV-33, -35 and -58) are
among the most closely related phylogenetically to the most prevalent HPV-16. The fourth (HPV-45) is the most closely
related to HPV-18; the second most prevalent type. We suggest that this may be an indicator of cross-immunity. Rates of
progression and clearance of clinical lesions were additionally estimated from longitudinal data gathered as part of the
same RCT. Our estimates of progression and clearance rates are consistent with the findings of survival analysis studies and
we extend the literature by estimating progression and clearance rates for non-16 and non-18 high-risk types. We anticipate
that such type-specific estimates will be useful in the parameterisation of further models and in developing our
understanding of HPV natural history.
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Introduction
Persistent infection with high-risk human papillomavirus (HPV)
has been shown to be the necessary precursor of progression to
cervical cancer [1,2,3]. The introduction of two prophylactic
vaccines and the advent of new screening technologies have led to
a surge in the number of HPV modelling studies. Such analysis
can give insight into, for example, the epidemiological impact of
combined HPV testing and conventional Pap smear screening; the
marginal effect of screening in vaccinated populations or the effect
of population-level behavioural heterogeneity on the impact of a
screening or vaccination programme. The combined usefulness
and challenge of modelling is the understanding and quantification
of uncertainty. HPV infection has a particularly complex natural
history: an initial infection may lead to the development of clinical
lesions which either progress to a more severe grade of neoplasia
or clear spontaneously. The more advanced the lesion, the lower
the chance of viral clearance [4,5]. Also, the risk of progression to
high-grade lesions, and then subsequently to carcinoma, is higher
for some HPV types than others: 70% of cervical cancers are
associated with either HPV-16 or HPV-18 [6,7,8,9]. Consequent-
ly, HPV modellers must make judicious choices of model structure
and prior ranges for parameters determining e.g. the transmissi-
bility of infection, rates of progression and clearance of clinical
lesions and the rate of waning natural immunity following
infection. Some HPV models of the early vaccine era were
parameterised with one pre-specified set of parameters, assessing
the sensitivity of model outcomes to each parameter in turn
[10,11,12]. This approach limits the understanding of the
interaction between input parameters. Both these studies and
others [13,14] derived HPV natural history parameters from
cohort studies in the epidemiological literature [2,15,16,17].
However, such clinical studies are limited by wide intervals
between follow-up appointments (which may allow multiple events
to occur), unclear distinctions between the diagnosis of neoplastic
grades and, in the case of estimating progression rates to cancer,
ethical considerations. For this reason, there has been a move
towards inferring HPV natural history parameters by fitting
mathematical (mechanistic) models of HPV transmission and
progression to point prevalence data on HPV infection and disease
states. By so doing, it is possible to incorporate prior knowledge
about the progression of infection and the protocols for screening
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and treatment in the study population. Early work on such
inference of HPV-related parameters relied on obtaining a visually
good fit between model projections and observed data [13,18,19].
Such an approach gives insight into model structures and
parameter values that will yield a good fit to data but these are
multiple and various [5]. Recently Kim et al. [20], Van de Velde
[21] and Jit et al. [5] have evaluated the goodness of fit between
model output and observed data for a wide range of possible
model structures and systematically chosen parameter values and
Bogaards et al. [22] have applied Markov Chain Monte Carlo
(MCMC) techniques to characterise posterior distributions for the
rates of transmissibility and waning natural immunity of 14 high-
risk HPV types. These developments have allowed the beginnings
of quantitative understanding of both the uncertainty and
sensitivity of HPV natural history parameters. Such an insight is
crucial to confident predictions of vaccination or screening
programme effectiveness.
We have aimed to infer the viral transmissibility, rate of waning
natural immunity and rates of progression and clearance of
infection of 13 high-risk HPV types and for HPV-6 and -11,
making use of two rich epidemiological datasets and a compre-
hensive survey of sexual activity from Sweden. Estimates of viral
transmissibility, clearance of initial infection and waning immunity
were derived in a Bayesian framework by fitting a susceptible-
infectious-recovered-susceptible (SIRS) transmission model to age-
and type-specific HPV prevalence data from both a cross-sectional
study and a randomised controlled trial (RCT) of primary HPV
screening. Rates of progression and clearance of clinical lesions
were estimated from longitudinal data gathered as part of the same
RCT. Where possible we compare our estimates of these
parameters with those derived from similar studies.
Materials and Methods
HPV Transmission Model
We developed a deterministic model of heterosexual partner-
ship formation, mono-type HPV transmission and the potential
progression to cervical cancer for each of 13 high-risk HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) and for HPV-
6 and -11. We model an age- and sexual activity- structured
population with two sexual activity groups for each of three age
brackets (14–29; 30–60 and 60+) where the size of the high sexual
activity group is a fixed proportion (15%) of the overall population,
regardless of age. Contact rates for each of these six age/sexual
activity groups were derived from the Swedish sexual activity data
gathered as part of the Sex in Sweden study [23], see Parameterisation
and Data. These data also informed the boundaries of the age
brackets.
We assumed an SIRS structure for HPV infection in both men
and women, allowing for an SIR structure in the limit where the
rate of waning natural immunity, estimated within this analysis,
tended to zero. The infected (I) compartment for females was
divided into five sub-compartments, corresponding to the
progression of HPV infection to disease: Initial infection, CIN1,
CIN2, CIN3 and Cancer (where CIN stands for Cervical
Intraepithelial Neoplasia). Women with an initial infection may either
progress to CIN1-type lesions at a rate of or naturally clear the
virus at a rate of x1. The rate of clearance of infection in males was
considered equal to the rate of natural clearance in women [24].
Women with CIN-type lesions either progress to higher-grade
lesions and then to cancer in a stepwise fashion (at a rate
dependent on stage, m2::m4) or clear the virus at rate dependent on
stage (x2 for CIN1 and x3 for CIN2/3 lesions). Note that the
clearance rate for CIN2 and CIN3 lesions is assumed to be the
same; this allows for the scarce data available on infections of these
grades and uncertainty in the clinical classification between CIN2
and CIN3. We did not consider spontaneous clearance at the
cancer stage. The model structure for high-risk HPV transmission
and progression is shown in Figure 1. HPV-6 and HPV-11 and all
HPV types in men were modelled using a simple SIRS structure
without sub-division by progression stage. Equations for the partial
differential equations employed are given in the Supplementary
Material (S1).
It was assumed that only the initial infection with HPV and
lower-grade cervical disease (CIN1 and CIN2-type lesions) are
infectious. Also, the force of infection was calculated assuming that
viral transmissibility bð Þ is independent of gender, age, sexual
activity class and stage of infection. Thus the force of infection
acting on females is:
l1,i(a,t)~b
X2
j~1
ð
c1,i,j(a,a
0)
I12,j(a
0,t)
N2,j(a0,t)
" #
where state variables take the form
Ihg,j(a
0,t)
with
h: indicating sub-division of the infected stage, I . In the case of
males this takes only the value 1.
g: gender (1 = females, 2 = males)
i,j: sexual activity groups of the subject and his/her partner
respectively
a’: used to denote the age of people of the opposite gender, g’
The state variables used in the model are summarised in the
Supplementary Material.
cg,i,j(a,a’) is the annual partnership formation rate, described
below
and
N2,j(a
0,t)~S2,j(a0,t)zI2,j(a0,t)zR2,j(a0,t)
is the total population of males, (g~2).
The force of infection acting on males depends on the number
of females in each of the three infectious I compartments:
l2,i(a,t)~b
X2
j~1
ð
c2,i,j(a,a
0)
I11,j(a
0,t)zI21,j(a
0,t)zI31,j(a
0,t)
N1,j(a0,t)
" #
where the total population of females
N1,j(a,t)~S1,j(a,t)z
X5
h~1
Ih1,j(a,t)zR1,j(a,t)
At demographic equilibrium, Ng,i(a,t):Ng,i(a) and therefore
henceforth we disregard the temporal dependence of population
size.
Mixing in the model is determined on a proportionate random
basis i.e. without accounting for either assortativity on the basis of
either age or sexual activity group. In order to balance the number
of partnerships between males and females we assume that females
adjust their behaviour completely to the number of partnerships
Inference of HPV Natural History Parameters
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sought by males. This leads to the simplistic conclusion that the
overall rate of partnerships formed between females of age (a) and
sexual activity group with males of age (a’) sexual activity group is:
c1,i,j(a,a
0)~
N2,j(a
0)c2,j(a0)
N1,i(a)
Cervical screening was incorporated into the model accord-
ing to the Swedish screening protocol. In Sweden, women are
screened at 3-yearly intervals between the ages of 23 and 50
and at 5-yearly intervals between 51 and 60. Uptake is 79% (J.
Dillner, personal communication) and we made the limiting
assumption that this rate is independent of sexual behaviour.
Treatment is provided for screened women with CIN2+ lesions
and cancer, resulting in the clearance of infection; the
combined rate for screening and subsequent successful
treatment is p.
We assumed that the rates of waning immunity and clearance of
initial infection are independent of age, gender, sexual activity and
personal history of HPV infection.
Parameterisation/Data
Sexual behaviour in the model (e.g. partnership formation rates)
was parameterised using data from a comprehensive Swedish
sexual activity survey (n = 2810). Complete details of the survey
have been published in ‘Sex in Sweden’ [23].
Estimation of Partner Acquisition Rates
As described above, the rate of partner acquisition, cj(a),
defined as the number of new partners per year, varies
according to age (a) and sexual activity group (j).These rates
were estimated fitting a mixture of Poisson distributions to data
using an MCMC routine. The data used were the annual rates
of new partners, stratified by gender and age, from the Swedish
sexual activity survey (Lewin et al., 2000). The rationale for
deriving partner acquisition rates is outlined below:
Given a certain annual rate of partner acquisition (c) for a
subpopulation, we would expect the number of new partners per
year (k) to be Poisson-distributed:
P kjcð Þ~ c
ke{c
k!
We consider males and females, and each age group, separately.
Defining a priori, the number (j) and proportions rj of each sexual
activity group, we can describe the overall probability of having a
certain number of partners (k) as a mixture of Poisson
distributions:
P(k)~
X
J
rjP kjcj
 
where cj is the partner acquisition rate for sexual activity group j.
Since we have data on the number of new partners per year,
stratified by age (ma), we can estimate the rates cajwith an MCMC
routine, maximising the likelihood
P m(k)jcj
 
~P
k
X
j
rjP kjcj
 ( )m(k)
again considering each age group separately.
Figure 1. The Susceptible-Infectious-Recovered-Susceptible (SIRS) model of high-risk Human Papillomavirus (HPV) transmission and
potential consequent progression to cervical cancer. Susceptible individuals become infected at a rate proportional to the force of infection l.
Following infection, they may progress in a stepwise fashion to neoplastic lesions of increasing severity (CIN1, CIN2, CIN3) and then to cancer (with
rates ). Alternatively, they may spontaneously clear the infection from any pre-cancerous stage (with rates ). High-grade clinical lesions (CIN2 and
CIN3) may be identified by cytological screening and successfully treated (at a rate p). Following viral clearance or successful treatment of lesions,
women retain an immunity to re-infection with the same HPV type. This immunity wanes at rate k, precipitating a return to the Susceptible
compartment.
doi:10.1371/journal.pone.0049614.g001
Table 1. The estimated annual rates of new partner acquisition for males and females in each of the three age and two sexual
activity groups.
Males Females
Age Low sexual activity High sexual activity Low sexual activity High sexual activity
14–29 0.54 4.11 0.25 2.89
30–59 0.05 0.64 0.07 1.47
60+ 0.01 0.21 0.02 0.11
doi:10.1371/journal.pone.0049614.t001
Inference of HPV Natural History Parameters
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In the parameterisation of this model, we considered two
sexual activity groups, the high sexual activity group, (j~2),
accounting for 15% of the population. We set the condition that
c1vc2.
The proposal densities were standard Normal distributions
with standard deviation dependent on the sexual activity
group:
s:d: jð Þ~ j
J
 2
xﬃﬃﬃﬃ
N
p
where x is a scaling constant and N is the total population size.
Since the higher sexual activity group has a smaller population,
it is more difficult to fit the likelihood than for the larger low sexual
activity group. For this reason we specified a prior function of
exponential form: e{x cj :
The consequence of this was to penalise higher contact rates,
essentially attempting to describe the data with rates as low as
possible. The resultant estimated annual rates of new partner
acquisition are shown in Table 1.
Data
In order to estimate the per-partnership viral transmissibility
bð Þ, annual rate of clearance of initial infection x1ð Þ and annual
rate of waning natural immunity kð Þ, the model was fitted to both
data from the Swedescreen trial and also data from the Swedish
voluntary Chlamydia screening programme.
Swedescreen is a prospective randomised controlled trial of
12,527 women, aged 32–38, attending population-based
Figure 2. The predicted endemic prevalence of type-specific HPV infection in sexually active women and the observed prevalence
in both women attending voluntary Chlamydia screening (solid dots) and those tested at baseline in the Swedescreen study
(hollow dots). The median predicted prevalence for each type is represented by the solid curve and the turquoise bands represent the 50%, 70%,
90% and 95% posterior intervals.
doi:10.1371/journal.pone.0049614.g002
Table 2. The assumed equivalence between histological and
cytological test results used in estimating rates of disease
progression and clearance.
Histological test Cytological test
Within normal limits Within normal limits
Koilocytosis
CIN1 ASCUS/LSIL
CIN2/3 HSIL
doi:10.1371/journal.pone.0049614.t002
Inference of HPV Natural History Parameters
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invitational cervical screening in Sweden. Women were
allocated in a 1:1 ratio to either receive an HPV test as well
as a cytology test (intervention) or a cytology test alone
(control). HPV positive women were invited for a second HPV
test at least twelve months later and women with persistent
infections were invited to colposcopy. Women were then
followed with comprehensive registry-based follow-up. Fur-
ther details of the study have been published elsewhere
[25,26,27].
The data from the Swedish voluntary Chlamydia screening
programme provided information on the prevalence of each of
the 13 high-risk HPV types, by age in women aged between 14
and 50 (N = 32,693). Although attendance rates for Chlamydia
screening in Sweden are high (J. Dillner, personal communi-
cation), we anticipate that the very young (,17) and older
women (.35) who attend elective screening are more likely to
be at higher risk. We accommodated this in the model by
specifying that a higher proportion of the high than the low
sexual activity groups attended Chlamydia screening.
Estimation of Progression and Clearance Rates for CIN-
type Lesions
Six type-specific HPV progression and clearance rates of
CIN1+ lesions were estimated from longitudinal data gathered
as part of a large prospective randomised controlled trial of
HPV testing and screening in Sweden (Swedescreen, see
Parameterisation and Data). These rates were inferred from a
corresponding vector of cumulative risks, derived from the
observed 6-, 12- and 24-month proportions of viral clearance
or disease progression among women with high-risk HPV
infection. These rates were:
m1: the rate of progression from initial HPV infection to
C(G)IN1- type lesions
m2: the rate of progression from C(G)IN1 to C(G)IN2 - type
lesions
m3: the rate of progression from C(G)IN2 to C(G)IN3 - type
lesions
m4: the rate of progression from CIN3 or CGIN3 - type lesions
to squamous cell carcinoma or adenocarcinoma respectively
X2: the rate of clearance of C(G)IN1- type lesions
X3: the rate of clearance of C(G)IN2 and C(G)IN3– type lesions
These parameters were informed by a corresponding vector
j of cumulative risks, as derived from the longitudinal data of
HPV-related disease progression among women tested positive
for high-risk HPV infection at the baseline of the Swedescreen
trial. The vector of cumulative risks is defined as follows:
j1
j2
j3
j4
j5
j6
2
666666664
3
777777775
~
1{e{t1m1
1{e{t2m2
1{e{t3m3
1{e{t4m4
1{e{t5x2
1{e{t6x3
2
666666664
3
777777775
where
j1: the cumulative proportion of women with a high-risk HPV
infection and normal cytology at baseline who were found to have
borderline or mildly abnormal cytology after 24 months (t1 = 2
years)
j2: the cumulative proportion of women with borderline or
mildly abnormal cytology (CIN1) for the first time within the
study, who were diagnosed with CIN2-type lesions after 6 months
of follow-up (t2 = 0.5 years)
j3: the cumulative proportion of women with CIN2-type lesions
for the first time within the study who were diagnosed with CIN3-
type lesions after 12 months (t3 = 1 year)
j4: the cumulative proportion of women with CIN3-type lesions
for the first time within the study who were diagnosed with cancer
after 24 months (t4 = 2 years)
j5: the cumulative proportion of women with a high-risk HPV
infection at baseline and borderline or mildly abnormal cytology
(CIN1) for the first time within the study, who were found to have
normal cytology after 12 months (t5 = 1 year)
j6: the cumulative proportion of women with advanced CIN2
or CIN3-type lesions for the first time within the study, who were
found to have normal cytology after 12 months (t6 = 1 year)
As outlined in Bogaards et al. [28], development of undiag-
nosed high-grade lesion among women with abnormal cytology at
baseline is offset by the belated diagnosis of lesions that were
already present at baseline, so the overall effect on the estimation
of rates of progression to higher-grade lesion is very small.
There is an art to deciding after what time lag (t) each
parameter should be estimated: not so long that the disease has
progressed by two or more stages but not so short that pending
progression or clearance has not yet taken place. We made several
estimates, corresponding to a few time points, estimating rates
from each of them. The value for t was chosen to be the shortest
Table 3. The estimated rates of progression and clearance of CIN1-type lesions in four high-risk HPV types.
ANNUAL RATE 16 18 31 33 OHR
Progression of HPV to CIN1 0.026 (0.007, 0.045) 0.058 (0.000, 0.179) 0.039 (0.008, 0.073) 0.046 (0.000, 0.147) 0.020 (0.004, 0.040)
Progression of CIN1 to CIN2 0.042 (0.010, 0.087) 0.111 (0.000, 0.255) 0.069 (0.000, 0.182) 0.182 (0.000, 0.406) 0.111 (0.048, 0.192)
Progression of CIN2 to CIN3 0.124 (0.024, 0.235) – 0.136 (0.024, 0.240) 0.105 (0.000, 0.357) 0.169 (0.072, 0.276)
Progression of CIN3 to Cancer 0.026 (0.000, 0.080) – – – –
Clearance of CIN1 1.468 (0.893, 2.043) 1.257 (0.286, 2.197) 1.136 (0.531, 1.672) 1.386 (0.365, 2.197) 1.212 (0.766, 1.645)
Clearance of CIN2+ 1.082 (0.710, 1.438) 0.884 (0.148, 1.695) 0.496 (0.191, 0.833) 0.788 (0.201, 1.299) 0.606 (0.393, 0.822)
To facilitate comparison with other studies, the grouping OHR includes types -31 and -33. Results presented are the median and 95% adjusted bootstrap confidence
interval. There were insufficient data available for non-16 types to be able to infer the progression rates of CIN3 to cancer and, in the case of HPV-18, the rate of
progression from CIN2 to CIN3.
doi:10.1371/journal.pone.0049614.t003
Inference of HPV Natural History Parameters
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evaluated which was greater than 1/(its estimated progression
rate). A bootstrap confidence interval (10,000 replications) was
estimated for each progression and clearance rate.
Assumptions
One limitation of the Swedescreen data was that each
woman received only one HPV test as part of the Swedescreen
trial – at baseline. As a consequence of this, it was necessary to
assume that her history of infection and disease progression
was attributable to the HPV type(s) that were identified at her
baseline HPV test. Also, since it was not therefore possible to
demonstrate clearance of infection, we assumed that a
reversion of abnormal to normal cytology was an indicator of
clearance of HPV.
Within the Swedescreen study, histological tests were only
conducted if the results of a cytological test were positive. To paint
a fuller picture of disease progression, we decided to include both
cytological and histological data in our estimation of rates from
longitudinal data. To do so, we considered equivalence between
the grades shown in Table 2.
Figure 3. Estimated rates of progression to disease. (A) The estimated rates of progression of infection with HPV-16, HPV-18 and other high-
risk (OHR) HPV types to CIN1-type lesions. We compare the rates estimated from the longitudinal Swedescreen data with the model-based estimates
of Jit et al. [5] and Van de Velde et al. [21]. (B) The estimated rates of progression of CIN1-type lesions attributable to HPV-16, HPV-18 and other high-
risk (OHR) HPV types to CIN2-type lesions. We compare the rates estimated from the longitudinal Swedescreen data with the model-based estimates
of Jit et al. [5] and Van de Velde et al. [21].
doi:10.1371/journal.pone.0049614.g003
Inference of HPV Natural History Parameters
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In cases of a cancer diagnosis, we always relied on the definition
from the histological test.
We assumed that development of disease was attributable to a
hierarchy of HPV types: if a woman was infected with HPV-16
this was considered the cause of any cytological abnormalities; if
she was infected with HPV-18 but not HPV-16, HPV-18 was
considered the cause. To estimate rates for the other high-risk
types (OHR) independently, we considered all women who tested
positive for the type in question and negative for -16 and -18. This
meant that we included in the estimation of OHR type progression
and clearance, women who were co-infected with a number of
OHR types. This was deemed necessary since many of the rarer
types were only found in cases of co-infection with several OHR
types.
In order to increase the effective sample size of women
progressing from one state to another, we considered the first
occurrence of a certain histological state for each woman to be
her ‘baseline’ test at that level. For example, to estimate the
rate of progression from CIN2 to CIN3 (m3), we considered not
only the women who were found to have CIN2 lesions at the
baseline of the Swedescreen study, but all women who were
found to have CIN2 lesions for the first time within the study;
essentially the clock starts ticking as soon as her CIN2
diagnosis is made.
Estimation of Further HPV-related Rates (HPV
Transmissibility, Clearance of Initial Infection and Waning
Immunity)
Type-specific estimates of the per-partnership transmissibil-
ity bð Þ, the annual waning resistance of natural immunity (k)
and the annual cumulative clearance rate of initial infection
x1ð Þ were estimated by fitting the deterministic model to two
cross-sectional datasets, namely i) age- and type-specific
prevalence of both high- and low-risk HPV types in men and
women, aged 14–50, presenting for Chlamydia screening xð Þ
Figure 4. Comparison of the estimated annual rates of clearance of initial infection between 13 high-risk HPV types and HPV-6 and
-11. The vertical line signifies the median of the median rates for all fifteen types; horizontal bars represent the 95% posterior intervals.
doi:10.1371/journal.pone.0049614.g004
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and ii) age- and type-specific prevalence of progressive cyto2/
histological states in women in the intervention arm of the
Swedescreen trial yð Þ. In the first instance, the progression and
clearance rates estimated from the longitudinal data were also
allowed to vary within prior ranges defined by their estimated
bootstrap confidence intervals (see Supplementary Material) but
since it was found that the resultant posterior distributions
were not noticeably responsive to these parameters, the rates
were fixed at their median values. The following Bayesian
model framework was used:
p b,k,x1jx,yð Þ!p xjf b,k,x1f gð Þ
p yjg b,k,x1f gð Þp bð Þp kð Þp x1ð Þ
The likelihood function for the Chlamydia screening
programme HPV prevalence data, p xDf b,k,x1f gð Þ is a straight-
forward multivariate Binomial with success probability
f b,k,x1f g, whereas the likelihood function for the Swedescreen
data for prevalence by stage, p yDf b,k,x1f gð Þ is a multivariate
Multinomial with success probability g b,k,x1f g.
The function g b,k,x1f g is simply the probability function
P X1~x1, . . . ,Xn~xnð Þ~ N!
Pni~1xi!
Pni~1h
xi
i
where
X1,X2,…,Xn. are a set of random variates
1::n are non-negative integers such that
Figure 5. Annual rates of clearance of HPV infection. (A) Comparison of the estimated annual rates of clearance of initial HPV-16 infection in
this and six further studies. The vertical line signifies the median of the median values of all seven studies. (B) Comparison of the estimated annual
rates of clearance of initial HPV-18 infection in this and five further studies. The vertical line signifies the median of the median values of all six studies.
(C) Comparison of the estimated annual rates of clearance of initial HPV-31 infection in four further studies. The vertical line signifies the median of
the median values of all five studies.
doi:10.1371/journal.pone.0049614.g005
Inference of HPV Natural History Parameters
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Xn
i~1
xi~N
and hi are constants with hiw0and
Xn
i~1
hi~1
Thus we are able to jointly consider the ‘success’ probability of
being in the susceptible state, the initial infection state, the CIN1
state and so forth.
Each of the 13 high-risk HPV types was modelled separately.
Estimates of the three natural history parameters were derived
from posterior distributions of the Markov Chain Monte Carlo
(MCMC) chains (chain length = 20,000) using the Metropolis-
Hastings algorithm [29]. The prior distribution for per-partnership
transmissibility, p(b), was uniform on ½0,1, for annual rate of
clearance of initial infection, p(x1), was uniform on ½0,5 and the
inverse of p(k), the duration of infection-induced immunity in
years, was uniform on ½0,100. Since a preliminary analysis
attempting to infer the rate of loss of infection-induced immunity,
1=k
 
, led to a posterior heavily skewed towards zero, it was
decided to estimate the duration rather than the rate. This
tendency of the rate of loss of immunity towards zero is suggestive
of an underlying SIR process but, in setting the prior for duration
of immunity from 0 to 100 years, we still allow for the possibility of
an SIRS model structure. This is consistent with the observation
by Baussano et al. [30] that other modelling studies [20,21,31]
have found it necessary to assume some measure of induced or
long-lasting immunity in order to achieve a good model fit.
In each iteration of the algorithm, a proposal for b,x1,kf g was
sampled from a multivariate normal distribution with standard
deviation 0.04 times the range of the corresponding prior density.
The deterministic model was then run for this proposal set and the
likelihood calculated as detailed in the main body of the paper.
The proposal parameter set was then accepted with a probability
determined by the ratio of its posterior density to that of the
previous set.
For each type the algorithm was run for a chain of length
n = 20,000. Visual inspection confirmed that the Metropolis-
Hastings algorithm converged swiftly to the posterior distribution
and parameter estimates were made rejecting a ‘burn-in’ period of
100 iterations. Examples of the MCMC traces are shown in
Figures S1 and S2 for HPV-16 and HPV-45 respectively. We
report 95% posterior intervals for the posterior distributions of all
MCMC-estimated parameters. These are obtained from the 2.5th
and 97.5th percentiles of all iterates after the burn-in period.
Results
The observed age-dependent prevalence of high-risk HPV
infection was accurately replicated by the appropriate type-specific
model for each type (see Figure 2). In general, a good fit to the data
was observed, with the model able to replicate the rapid
acquisition of markers, the peak in prevalence in women in their
twenties, and the decline thereafter. In the cases of HPV-33, -35, -
45 and -58, the models over-estimated the prevalence of infection
with respect to the data. This was not due to a failure of the
Markov chain to converge (see Supplementary Material; further data
available on request). The prevalence of HPV-16 infection in
women taking part in the Swedescreen trial was higher than those
of the same age (32–38) attending Chlamydia testing, HPV-18 and
HPV-33 were observed at closely comparable levels in both studies
but all other high-risk types were less prevalent in the former
group. This disparity probably represents the higher representa-
tion of highly sexually active women in the voluntarily attending
Chlamydia screening in their mid-thirties.
Estimation of Progression and Clearance Rates of CIN-
type Lesions
The median estimated rates of progression and clearance of
CIN1-type lesions in four high-risk HPV types, each with a 95%
adjusted bootstrap confidence interval, are given in Table 3. Due
to a paucity of data on some of the rarer high-risk types, it was not
possible to estimate each progression/clearance rate for each of
the 13 high-risk types. Thus we estimated rates for ‘other’ high-risk
(OHR) types by pooling data. To facilitate comparison with other
studies, the grouping OHR excludes only HPV-16 and HPV-18,
even though we had been able to estimate some rates for types -31
and -33.
The progression and clearance rates did not differ significantly
between HPV types. However, HPV-16 appeared to progress
from initial infection to CIN1- type lesions at an annual rate of
0.026 (0.007–0.045), somewhat more slowly than HPV-18 which
had an annual rate of 0.058 (0–0.179) but at a similar rate to other
high-risk types (OHR) which had an annual rate of 0.02 (0.004–
0.04).
Figure 3 shows the comparison of our data-derived rates of
progression of CIN1- and CIN2-type lesions with the estimates of
Jit et al. [5] and Van de Velde et al. [21].
Estimation of Clearance Rate of Initial Infection
The rate of clearance of type-specific initial HPV infection was
well characterised by the posterior distribution of the MCMC
Table 4. The estimated rates of transmissibility for thirteen
high-risk HPV types and HPV-6 and -11.
HPV type Median 95% posterior interval
Lower Upper
6 0.755 0.295 1.000
11 0.741 0.256 1.000
16 0.718 0.286 1.000
18 0.736 0.292 1.000
31 0.743 0.292 1.000
33 0.752 0.268 1.000
35 0.746 0.264 1.000
39 0.755 0.233 1.000
45 0.739 0.279 1.000
51 0.755 0.233 1.000
52 0.745 0.317 1.000
56 0.743 0.253 1.000
58 0.758 0.311 1.000
59 0.745 0.252 1.000
66 0.757 0.275 1.000
Results presented are the median and 95% posterior interval.
doi:10.1371/journal.pone.0049614.t004
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chain, with a median posterior/prior ratio of 0.320 across all HPV
types. The median values for the rate of clearance of initial
infection did not differ significantly between types (see Figure 4).
Our estimated clearance rates tended to be lower than the
estimates of Trottier et al. [16] from data on HPV infection
among women in Sa˜o Paulo, Brazil but were in line with other
cohort studies for the types where estimates exist (see Figure 5).
Although few estimates have been made of the annual clearance
rates of some of the rarer high-risk HPV types, more cohort studies
have concentrated on estimates for HPV-16, -18 and the grouped
other high-risk (OHR) types. In Figure 5 we compare our
estimates with those of four further cohort studies and with the
model-based estimates of Van de Velde et al. [21]. The confidence
intervals of our estimates overlap with those of the other studies.
Figure 6. Comparison of the estimated annual rates of waning immunity for 13 high-risk types of HPV with those estimated by
Bogaards et al. [22]. The vertical line signifies the average of the posterior median estimates across all types in both studies.
doi:10.1371/journal.pone.0049614.g006
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Estimation of Transmissibility
The median estimated rates of transmissibility in the thirteen
high-risk HPV types, each with a 95% adjusted bootstrap
confidence interval, are given in Table 4. The median estimates
were not significantly different, ranging from 0.718 (0.286–1.000)
for HPV-16 to 0.758 (0.311–1.000) for HPV-58. In fact, the
posteria of all thirteen transmission probabilities were skewed
towards the inherent upper bound of 1.
Estimation of Rate of Waning Immunity
The estimated rates of waning natural immunity (or resistance
to subsequent infection) are shown in Figure 6. Our estimates do
not differ significantly from those of Bogaards et al. [22] but the
posterior median values are consistently lower, corresponding to 5-
year cumulative proportions of clearance of 6%–12% across the
13 types (annual rates of 0.015–0.027). HPV-16 was among those
with the highest median estimates with an estimated 5-year
cumulative proportion of clearance of 11.4% (5.4%–15.0%). Such
low rates of waning natural immunity imply that the protection
conferred by infection with a certain HPV type might indeed be,
at least for some, life-long; an assumption held in other modelling
studies [13,32].
Discussion
We have made estimates for the transmissibility, clearance and
progression rates and rates of waning natural immunity for 13
high-risk types of HPV by using Swedish behavioural and
epidemiological data to fit an ensemble of deterministic models
of HPV transmission and progression. The datasets used included
the ‘Sex in Sweden’ sexual behaviour survey, longitudinal data on
HPV prevalence and clinical disease progression from the
randomised controlled trial of HPV testing, ‘Swedescreen’, and
HPV type-specific prevalence data gathered as part of the Swedish
voluntary Chlamydia screening programme. The analysis was
formed of two stages. Firstly, rates were estimated for the stepwise
progression of different HPV types to disease of increasing clinical
severity and of clearance of different grades of late-stage infection.
Secondly, these estimated rates were incorporated into a
monotype SIRS-structured deterministic model of the transmis-
sion and progression of HPV. This model was then fitted to HPV
prevalence data using a Markov Chain Monte Carlo (MCMC)
routine, in order to estimate the transmissibility, rate of clearance
of initial infection and rate of waning natural immunity of each
type in turn.
It was observed that the models over-estimated the observed
prevalence of four of the high-risk types. We suggest that this is an
artefact of modelling the HPV types independently. Three of these
types (-33, -35 and -58) are, in fact, three of the most closely
phylogenetically-related to HPV-16; the most prevalent type.
HPV-45 is the most closely related to the second most prevalent
type, HPV-18. It is feasible that this similarity leads to cross-
immunity between the types, effectively reducing the number of
young women susceptible to infection with types -33, -35, -45 and -
58.
We found variation in the rates of clearance of initial infection
to be a very informative parameter in the fitting of type-specific
models of HPV prevalence to data, indicating that this may be an
important determinant in the differing prevalences between types.
The lowest rates of clearance of initial infection were observed in
HPV-16, -18 and -31, the most prevalent of the high-risk HPV
types. This would again support the theory that higher prevalence
is associated with persistence of infection, though we would agree
with Bogaards et al. [22] that this does not preclude a role for
transmissibility and immunity.
Our estimates of transmissibility did not differ significantly
between types although there remained a large degree of
uncertainty. Our inferred values were in line with those estimated
in previous studies: the median per-partnership transmissibility of
HPV-16 was estimated to be 0.718 with a 95% posterior interval
of 0.286–0.999) compared with 0.8 estimated by Hughes et al.
[11]. However, values for all types were skewed towards the
maximum limit of 1. We suggest that this may be attributable
either to an underestimate in the sexual activity data or to the
assumption of proportionate random mixing by age and sexual
activity group, or to a combination of the two. Barnabas et al. [13]
had a similar finding, noting that survey data will tend to
underestimate sensitive sexual behaviour such as partner change
rates. This study has the further complication that the sexual
activity data used, although well matched to the study population
in geographical and demographical terms, predates the epidemi-
ological data used for fitting (and the time period of modelling
interest) by at least ten years. It is reasonable to suppose that sexual
behaviour trends in the intervening decade may well have given
rise to a higher HPV prevalence than that contemporaneous with
the sexual activity data, requiring an increase in the inferred
transmissibility to compensate. Alternatively, the inferred trans-
mission probabilities may have been pushed higher by assuming
completely proportionate mixing. In fact this is a very strong
assumption: age-dependent mixing in particular is known to be
assortative and concentration of transmission in certain age groups
may reduce the transmission probabilities needed to fit the
observed data.
The rate of waning immunity was estimated to be very low; the
5-year cumulative proportions of clearance varied between 6%–
12% across the 13 types. This would imply that few women
become susceptible to re-infection with any given HPV type and
that the observed decrease in the force of infection in the early
twenties is more likely to be due to immunity than to decreased
sexual activity. Indeed, our estimates of the rate of waning
immunity would imply that the protection conferred by infection
with HPV is effectively close to life-long.
We have also further contributed to the literature estimating
the rates of progression and clearance of clinical lesions due to
HPV, extending the field by deriving type-specific estimates of
progression rates up to CIN3-grade lesions for type -31 and 33
and clearance thereof. Our results implied that the rate of
progression of other high-risk types from CIN1 to higher grade
lesions was significantly lower than for HPV-16 and HPV-18,
indicating that their less prominent role in the cause of cervical
cancer may be due not solely to lower prevalence but also to an
inherently lower oncogenicity. Our estimates are similar to
others in the literature although they are subject to a large
degree of uncertainty, highlighting the benefit that would be
derived from pooling data on disease progression from
Swedescreen with those collected as part of other studies
elsewhere. Such collation would increase the power of the
analysis, ensuring more certainty in the inferred rates.
Although this analysis provides some useful new insight into
HPV-related parameters, it has some limitations. Firstly, the
nature of deterministic compartmental models means that it is not
possible to consider diversity in individual-level behaviour. For
example, we estimate here the per-partnership transmissibility of
HPV infection. In order to derive from this a per-act transmis-
sibility requires us to assume an ‘average’ partnership between a
susceptible and an infected partner. Also, we assume that all
women have an equivalent approach to screening and subsequent
Inference of HPV Natural History Parameters
PLOS ONE | www.plosone.org 11 November 2012 | Volume 7 | Issue 11 | e49614
treatment. Such an assumption belies the true underlying
heterogeneity; in fact, it is those women who do not attend
screening who are more likely to go on to develop high-grade
clinical lesions and cervical cancer. In considering the more subtle
questions policy-makers face in terms of vaccination and screening
programmes it is common for complex individual-based models to
be used. However, the fitting of these models is similarly complex
due to the long run times and inherent stochasticity of these
models. The type-specific estimates we have made here for HPV
transmissibility and rates of progression and clearance will
facilitate the parameterisation of such individual-based models
by, for example, providing prior ranges for natural history
parameters. These models will then, in turn, allow a more
thorough understanding of the complex natural history of HPV
infection and its implications for the efficacy of vaccine and
screening programmes in this new era of HPV prevention.
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Figure S1 MCMC traces (left) and posterior distribu-
tions (right) for estimation of HPV-16 parameters. The
MCMC chains (n = 20,000) and posterior distribution density are
shown for, in order, the transmissibility (b), cumulative clearance
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immunity kð Þ for HPV-45. The fourth row shows the trace and
distribution of the log-likelihood. The figures show a rapid
convergence.
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